Navrogen Announces The Closing Of $3.2M Funding To Support Its Humoral Immuno-Oncology Platform Discovery Technologies And Preclinical Pipeline
Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors.
Previous clinical studies have confirmed that tumors produce immune checkpoint factors that can suppress a patient’s immune response to dysregulated cancer cells. The most commonly studied factors have been those that suppress activation of CD8+ T-cells. The therapeutic and commercial success of antagonists against a subset of these checkpoint inhibitors has fueled the industry’s interest for developing additional drug candidates that can reverse immuno-suppressive mechanisms against T-cells. Alternatively, humoral immunity, which relies on antibody and complement mediated immune responses against dysregulated cancer cells, has recently been found to be suppressed by tumor-produced proteins, referred to as Humoral Immuno-Oncology (HIO) factors. These factors suppress patient’s endogenous humoral responses as well as the pharmacologic effects of antibody-based therapies such as Rituxan® and Herceptin®. Navrogen’s mission uniquely focuses on therapeutic solutions to reverse the immuno-suppressive mechanisms mediated by HIO-factors through proprietary screening platforms that identify tumor-derived proteins with HIO-factor activity as well as develop agents that can overcome a HIO-factor’s immuno-suppressive effects.
Read the full article here.